03). With a mean follow-up of 45.7 months, only 1 patient developed an asymptomatic parasacral hernia.
CONCLUSION: Reconstruction of posterior sacrectomy defects with HADM and gluteus maximus myocutaneous flaps may be valid. This approach may have
rates of wound dehiscence comparable to other techniques and low rates of parasacral herniation.”
“Interferon-alpha (IFN-alpha), a type I IFN, is a well-known antitumoral agent. The investigation of Selleckchem Verubecestat its clinical properties in acute myeloid leukemia (AML) has been prompted by its pleiotropic antiproliferative and immune effects. So far, integration of IFN-alpha in the therapeutic arsenal against AML has been modest in view of the divergent results of clinical trials. Recent insights into the key pharmacokinetic determinants of the clinical efficacy of IFN along NU7441 chemical structure with advances in its pharmaceutical formulation, have sparked renewed interest in its use. This paper reviews the possible applicability of IFN-alpha
in the treatment of AML and provides a rational basis to re-explore its efficacy in clinical trials. Leukemia (2011) 25, 739-748; doi: 10.1038/leu.2010.324; published online 28 January 2011″
“BACKGROUND: Pedunculopontine nucleus (PPN) stimulation is a novel therapy for Parkinson disease. However, controversies remain regarding the clinical application of this new therapy, including patient selection, electrode positioning, and how best to assess outcomes.
OBJECTIVE: To clarify the clinical application of PPN stimulation in Parkinson disease.
METHODS: Five consecutive www.selleck.cn/products/Bortezomib.html patients with Parkinson disease complicated by severe gait freezing, postural instability, and frequent falls (all persisting even while
the patient was on medication) received bilateral stimulation of the mid-lower PPN without costimulation of other brain targets. Outcomes were assessed prospectively over 2 years with gait-specific questionnaires and the Unified Parkinson Disease Rating Scale (part III).
RESULTS: The primary outcome, the Gait and Falls Questionnaire score, improved significantly with stimulation. Benefits were maintained over 2 years. Unified Parkinson Disease Rating Scale (part III) items assessing gait and posture were relatively insensitive to these treatment effects. Beneficial effects often appeared to outlast stimulation for hours or longer. Thus, single-session on-vs off-stimulation assessments may be susceptible to “”delayed washout effects.”" Stimulation of the PPN did not change akinesia scores or dopaminergic medication requirements.
CONCLUSION: Bilateral stimulation of the mid-lower PPN (more caudal than previous reports) without costimulation of other brain targets may be beneficial for the subgroup of patients with Parkinson disease who experience severe gait freezing and postural instability with frequent falls, which persist even while on medication.